Dropzone19 Apr 2018 10:58
Blatant ramping? Sorry for "ramping" fundamentals - in summary for those that cant be bothered to read:
1) Valued at less than cash.
2) Next deal "2nd quarter of 2018".
3) hVIVO has generated the largest human disease database in the industry (worth NADA on the price at the moment)
4) "has already generated significant interest from global pharmaceutical companies"
5) "Non-Dilutive" funding options in place. ("we plan to leverage non-dilutive funding to advance this invention through government grants and collaborations.)
6) "time, we anticipate that this intellectual property will generate a future revenue stream from licensing deals. "
7) Initiated and completed a first-in-man Phase I study for Imutex's mosquito-borne illness vaccine platform (AGS-v) at the National Institute of Allergy and Infectious Diseases(NIAID), part of the National Institute of Health (NIH):
- Results are expected in H2 2018.
8) " have begun expanding our offering to capture these significantly larger opportunities."
9) "a universal flu vaccine candidate designed to minimise the impact of the virus by reducing symptoms - potentially relegating flu to a much milder disease "
10) "achieved successful symptom based results, which we believe is a first for a universal flu vaccine candidate"
11) "In 2018, we anticipate progress of the FLU-v programme towards monetisation and/or non-dilutive funding for further development. "
12) "The Board is confident that the Company's strategy for growth will deliver significant shareholder value. "